Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients.
Alopecia
Alopecia androgénica
Androgenetic alopecia
Arrhythmia
Arritmia
Arterial hypertension
Blood pressure
Cardiopatía
Hair loss
Heart disease
Hipertensión arterial
Hipotensión
Hypotension
Presión arterial
Journal
Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
received:
23
06
2023
revised:
16
07
2023
accepted:
20
07
2023
pubmed:
1
9
2023
medline:
1
9
2023
entrez:
31
8
2023
Statut:
aheadofprint
Résumé
Systemic adverse effects (AE) are a major concern of low-dose oral minoxidil (LDOM) treatment, especially in patients with arterial hypertension or arrhythmia. The objective of this study was to evaluate the safety of LDOM in patients with hypertension or arrhythmia. Retrospective multicenter study of patients with hypertension or arrhythmia treated with LDOM for any type of alopecia. A total of 254 patients with hypertension [176 women (69.3%) and 78 men (30.7%)] with a mean age of 56.9 years (range 19-82) were included. From them, the dose of LDOM was titrated in 128 patients, allowing the analysis of 382 doses. Patients were receiving a mean of 1.45 (range 0-5) antihypertensive drugs. Systemic AE were detected in 26 cases (6.8%) and included lightheadedness (3.1%), fluid retention (2.6%), general malaise (0.8%), tachycardia (0.8%) and headache (0.5%), leading to LDOM discontinuation in 6 cases (1.5%). Prior treatment with doxazosin (P<0.001), or with three or more antihypertensive drugs (P=0.012) was associated with a higher risk of discontinuation of LDOM. LDOM treatment showed a favorable safety profile in patients with hypertension or arrhythmia, similar to general population.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Systemic adverse effects (AE) are a major concern of low-dose oral minoxidil (LDOM) treatment, especially in patients with arterial hypertension or arrhythmia. The objective of this study was to evaluate the safety of LDOM in patients with hypertension or arrhythmia.
PATIENTS AND METHODS
METHODS
Retrospective multicenter study of patients with hypertension or arrhythmia treated with LDOM for any type of alopecia.
RESULTS
RESULTS
A total of 254 patients with hypertension [176 women (69.3%) and 78 men (30.7%)] with a mean age of 56.9 years (range 19-82) were included. From them, the dose of LDOM was titrated in 128 patients, allowing the analysis of 382 doses. Patients were receiving a mean of 1.45 (range 0-5) antihypertensive drugs. Systemic AE were detected in 26 cases (6.8%) and included lightheadedness (3.1%), fluid retention (2.6%), general malaise (0.8%), tachycardia (0.8%) and headache (0.5%), leading to LDOM discontinuation in 6 cases (1.5%). Prior treatment with doxazosin (P<0.001), or with three or more antihypertensive drugs (P=0.012) was associated with a higher risk of discontinuation of LDOM.
CONCLUSIONS
CONCLUSIONS
LDOM treatment showed a favorable safety profile in patients with hypertension or arrhythmia, similar to general population.
Identifiants
pubmed: 37652097
pii: S0001-7310(23)00679-8
doi: 10.1016/j.ad.2023.07.019
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.